Myeloperoxidase and Atherosclerosis
| Autor: | Shobha H. Ganji, Vaijinath S. Kamanna, Moti L. Kashyap |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pharmacology
medicine.medical_specialty Acute coronary syndrome biology business.industry Inflammation medicine.disease Coronary artery disease chemistry.chemical_compound Endocrinology High-density lipoprotein chemistry Internal medicine Low-density lipoprotein Myeloperoxidase medicine Cardiology biology.protein Pharmacology (medical) Myocardial infarction Endothelial dysfunction medicine.symptom business |
| Zdroj: | Current Cardiovascular Risk Reports. 7:102-107 |
| ISSN: | 1932-9563 1932-9520 |
| DOI: | 10.1007/s12170-013-0291-3 |
| Popis: | Myeloperoxidase (MPO), a member of the peroxidase family, emerged as a major player in the initiation and propagation of atherosclerotic cardiovascular disease (CVD). Evidence for its role in atherosclerosis include that MPO: a) induces endothelial dysfunction, b) modifies physiologically functional high density lipoprotein (HDL) into “dysfunctional HDL”, c) converts low density lipoprotein (LDL) into more atherogenic modified LDL form, and d) induces endothelial cell death and tissue factor expression involved in plaque vulnerability. Elevated levels of blood MPO are associated with CVD, predict incident risks for myocardial infarction and cardiac death in subjects with acute coronary syndrome, and predict future risk of coronary artery disease (CAD) in healthy individuals. In this article, we review current understandings on the role of MPO in pathophysiological processes involved in atherosclerosis and CVD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink